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Abstract
Background Incidence of attention deficit hyperactivity
disorder (ADHD) in children and adolescents has been
increasing. The disorder results in high societal costs.
Policymakers increasingly use health economic evaluations
to inform decisions on competing treatments of ADHD.
Yet, health economic evaluations of first-choice medication
of ADHD in children and adolescents are scarce and gen-
erally do not include broader societal effects.
Objectives This study presents a probabilistic model and
analysis of methylphenidate osmotic-release oral system
(OROS) versus methylphenidate immediate-release (IR).
We investigate and include relevant societal aspects in the
analysis so as to provide cost-effectiveness estimates based
on a broad societal perspective.
Methods We enhanced an existing Markov model and
determined the cost effectiveness of OROS versus IR for
children and adolescents responding suboptimally to
treatment with IR. Enhancements included screening of a
broad literature base, updated utility values, inclusion of
costs and effects on caregivers and a change of the model
type from deterministic to probabilistic.
Results The base case scenario resulted in lower incre-
mental costs (€-5815) of OROS compared with IR and
higher incremental quality-adjusted life-year (QALY)
gains (0.22). Scenario analyses were performed to deter-
mine sensitivity to changes in transition rates, utility of
caregivers, medical costs of caregivers and daily medica-
tion dose.
Conclusions The results indicate that, for children re-
sponding suboptimally to treatment with IR, the beneficial
effect of OROS on compliance may be worth the additional
costs of medication. The presented model adds to the
health economic information available for policymakers
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and to considerations on a broader perspective in cost-ef-
fectiveness analyses.
Key Points for Decision Makers
There is a lack of economic studies on attention
deficit hyperactivity disorder (ADHD) in children
and adolescents with a broader societal perspective.
We present a probabilistic model of methylphenidate
osmotic-release oral system (OROS) versus
methylphenidate immediate-release (IR),
considering and integrating relevant broader societal
aspects.
The base case scenario resulted in lower incremental
costs (€-5815) of OROS compared with IR and
higher incremental quality-adjusted life-year gains
(0.22).
Scenario analyses showed particular sensitivity to
changes in transition rates.
The study contributes to the movement towards
broader societal considerations in cost-effectiveness
analyses and to the provision of comprehensive
health economic evidence for policymakers and
clinicians in mental health care.
Like other authors in the field, we recognize a lack of
data; future research should be especially directed at
the collection of empirical data on transition
estimates, utility values of caregivers and broader
societal aspects of the disorder, such as criminal
justice costs.
1 Introduction
An increasing incidence of attention deficit hyperactivity
disorder (ADHD) in children [1] and high use of pharma-
cological treatments [2] have become relevant issues for
policymakers and mental health professionals. It is yet
unclear whether the increase in incidence is due to changes
in true numbers of patients or whether numbers appear
higher as a consequence of differences in diagnosis or re-
call of parents [3]. The high number of young ADHD pa-
tients results in significant societal costs [4]. Evidence from
literature suggests that 50–70 % of those suffering from
ADHD in childhood also experience ADHD as an adult [5,
6]. Hence, costs are not limited to the short term; ADHD
may also result in lower household income, mental and
physical dysfunction, comorbidities and increased health
consumption later on in life [6, 7] as well as increased
health care consumption and productivity losses of
household members [8].
First-choice medication for treatment of ADHD in the
Netherlands is the stimulant methylphenidate (MPH) [9].
MPH is available as a short-acting as well as a more costly
long-acting formulation. Different formulations are avail-
able from a wide selection of brands and in different
strengths. Short-acting MPH requires accurate medication
intake 2–5 times a day [9]. Consequently, medication in-
take may require high effort and impose practical diffi-
culties, for example, on children attending school. The
long-acting formula has been developed to overcome those
practical problems of medication intake and compliance by
using a once-a-day treatment scheme [10]. Existing clinical
studies suggest no significant difference between the effi-
cacy of short-acting and long-acting MPH under the as-
sumption of full therapy compliance [10–12]. However, it
has been shown that lower frequency of medication intake
is correlated with better treatment compliance [13]. Long-
acting MPH has been shown to be associated with better
treatment continuity [14, 15]. Kemner and Lage [14] found
patients treated with long-acting MPH to be subject to less
breaks in medication use, fewer medication switches and a
longer period on intended therapy. Marcus et al. [15] stated
that the treatment duration of patients with long-acting
MPH was on average longer than for patients treated with
short-acting MPH. Long-acting formulations of MPH have
also been proven to result in superior compliance in pa-
tients when compared with the short-acting formulation
[16–18], hence, possibly leading to better effectiveness
than the short-acting formulation.
However, it is not evident whether the effect of long-
acting formulations of MPH can justify the higher costs.
Given the scarce financial resources in health care, cost-
effectiveness analyses have become essential to inform
policymakers’ choices between competing treatments and
to provide well-founded recommendations to clinicians
within clinical guidelines. However, evidence in the form
of recent state-of-the-art health economic evaluations of
ADHD treatment in children is limited. Furthermore, there
is increasing debate on whether it is sufficient to purely
evaluate interventions on the basis of costs and effects in
the domain of health care and limit these to the patient
alone [19]. Authors of recent publications emphasized the
lack of economic studies on ADHD in children and ado-
lescents with a broader societal perspective [20–22].
Bernfort et al. [21] found that most often societal costs
were not included in economic evaluations of ADHD. Wu
et al. [22] performed a systematic literature review on
health care costs of family members of children with
ADHD and found those costs to be higher than those of
families without a child with ADHD. Beecham [20] stated
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that ‘‘economic evaluation of interventions for child and
adolescent psychiatric disorders has lagged some way be-
hind its adult counterpart.’’ She expressed the need for a
broader perspective as to reflect the various effects of
psychiatric disorders in children and adolescents [20].
Evidence from the literature on meningitis [23] suggests
that ‘spillover’ health effects on family may constitute as
much as 48 % of the health effects on the patient. As
ADHD can be considered especially stressful on the direct
environment of the patient, such as parents, siblings,
friends or schoolmates, this percentage may even be larger
for patients with ADHD. Hence, the inclusion of broader
societal effects and costs is considered necessary [22].
Bernfort et al. [21] recommended the use of a health
economic Markov model to determine the long-term costs
and effects of ADHD. However, the authors stated that
sufficiently detailed data (especially on long-term conse-
quences of ADHD) was scarce or unavailable [21]. King
et al. [24] expressed their concerns on the limited avail-
ability of effectiveness estimates and utility values, possi-
bly due to scarcity of clinical data. Among the health
economic evaluations that have been performed to evaluate
various pharmacological treatments of ADHD are analyses
based on decision analytic trees [25] and cost-of-illness
calculations [26]. A small number of evaluations have been
performed based on more advanced health economic
(Markov) models [24, 27, 28]. However, there is a lack of
more recent studies in the field. An economic evaluation on
long-acting MPH osmotic-release oral system (OROS)
versus short-acting MPH immediate-release (IR) suggested
better cost effectiveness of OROS (hereafter referred to as
the Faber model) [29]. However, that evaluation was lim-
ited compared with the current standard of health economic
modeling as a deterministic model was employed and only
effects limited to the patient were included. Hence, clear
health economic recommendations on the cost effective-
ness of OROS compared with IR based on a broad societal
perspective are still lacking.
Knowledge of the cost effectiveness of treatment op-
tions for children with ADHD is essential in order to in-
form policymakers and enable the formulation of specific
recommendations in clinical guidelines. In the case of
MPH, it would be desirable to provide clear recommen-
dations on which formulation is to be preferred under
which circumstances, founded on sound and comprehen-
sive health economic evidence. This study aims to con-
tribute to this goal. We perform a cost-effectiveness
evaluation of OROS versus IR in line with current health
economic methodology, based on the Faber model [29], but
with a probabilistic model update, enhanced model struc-
ture, updated input parameters (including utility values)
and a broader societal perspective (i.e., we considered
criminal justice costs, educational costs, employment
disadvantages, out-of-pocket-expenses, medical and pro-
ductivity costs and utility values of the caregiver). Addi-
tionally, we provide specific recommendations for future
data collection, which would be valuable to further in-
crease the validity of the model outcomes.
2 Methods
We evaluated the cost effectiveness of OROS compared
with IR for patients with suboptimal response to IR. The
structure of the probabilistic Markov model and its pa-
rameters was defined according to the Dutch guidelines for
pharmacoeconomic evaluation [30].
According to health economic standards, a societal
perspective was taken to reflect costs and effects on pa-
tients, their parents and society as a whole [31]. We sear-
ched literature on a broad range of cost categories for
relevance and feasibility of inclusion in the model (i.e.,
criminal justice costs, lower income, out-of pocket ex-
penses of the patient as well as health care costs and pro-
ductivity costs of caregivers). Direct medical and non-
medical costs as well as spillover effects on caregivers
were included in the model.
2.1 Consultation of Experts
As part of this study, a panel of experienced psychiatrists
from various regions in the Netherlands was consulted
(Table 1). These experts were asked to provide feedback
on the model structure, input and model assumptions as
well as estimates of transition probabilities. Transition
probabilities were retrieved in accordance with the Delphi
panel requirements [30], and other issues were discussed
individually. After discussion with the expert panel on,
among others, the definition of health states and the cycle
length of the probabilistic model, the cycle length was
chosen to remain unchanged and the model states were
slightly adapted as opposed to the Faber model [29] to
better match patient characteristics, illness and treatment
approach.
2.2 General Model Characteristics
The probabilistic model was based on the existing deter-
ministic model by Faber et al. [29]. Model type, model
state definitions, time horizon, model parameters and
model input (including utility values) were updated to en-
hance the existing model and to comply with current health
economic methodology (Table 2).
As the Faber model was limited to a deterministic
decision-analytic model with sensitivity analyses, we
chose a more advanced probabilistic approach. The
Probabilistic Markov Model: Cost Effectiveness of OROS Versus IR MPH 491
consideration of uncertainty increasingly gains impor-
tance, as shown in several guidelines, of which one ex-
plicitly suggests the use of probabilistic sensitivity
analysis [33]. Therefore, input parameters were set to vary
according to prior distributions as to introduce parameter
uncertainty in the model.
Furthermore, we refined and improved model state
definitions. Where Faber et al. [29] considered five model
states (optimal, suboptimal, treatment stopped, functional
remission and non-compliance), with different states ap-
plicable for different treatment conditions, the current
model defined four model states (optimal, suboptimal,
Table 1 Consulted experts
Expert Gender Age
(years)
Specialism Subspecialism Years
experience
in mental
health
Average number of
patients
with ADHD from 6 to
18 years of age seen
per month
Years
experience
with
ADHD
medication
Average
number of
patients seen
per month
1 M 55 Child and youth
psychiatrist
None 24 90 16 105
2 M 52 Child and youth
psychiatrist
Hospital, child psychiatry
and ADHD
22 [30 16 [100
3 F 43 Child and youth
psychiatrist
ADHD/ODD/ticks 13 45 10 50
4 M 55 Child psychiatrist Neuropsychiatry 29 50 22 80
ADHD attention deficit hyperactivity disorder, ODD oppositional defiant disorder
Table 2 Current model vs. Faber model
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treatment stopped and remission) consistent across treat-
ment conditions.
The time horizon of the model was slightly adjusted in
the current model. Patients entered the Faber model [29] at
8 years of age and remained in the model for 10 years. In
the current model, we redefined the starting age of patients
entering the model to 6 years and extended the time hori-
zon to 12 years in order to be in line with the treatment
guidelines for ADHD [9]. The relevant patient population
was defined as patients within this age group who initially
had responded suboptimally to IR because of incorrect
intake of medication (i.e., missing doses of medication due
to administrative burden). To simulate a randomized
population, it was assumed that half of the initial patient
population continued to receive IR and the other half
switched to treatment with OROS when entering the
model.
Within the current model, the assumed cycle length was
1 day and was consistent with the set-up of the Faber
model. The panel of experts (Table 1) indicated that a
cycle length in line with the prescription regimen of a day
would be most appropriate and consistent as non-compli-
ance to medication would, on average, result in a change in
behavior on the same day for almost all children, with only
few exceptions. This cycle length implies that an im-
provement or worsening of compliance can occur on a
daily basis and symptoms and costs change accordingly
after 1 day. In reality, costs may adjust less quickly than
effects, resulting in less volatility in costs than assumed in
the model.
The prescribed dosage of medication was assumed opti-
mal for all patients based on age andmetabolism. In linewith
the Multimodal Treatment of attention deficit hyperactivity
disorder (MTA) study [34] and expert comments, a mean of
3 doses IR per day and 1 dose OROS per day were assumed.
Costs and effects were discounted at 4 and 1.5 %, re-
spectively, according to the Dutch guidelines for pharma-
coeconomic research [30].
2.3 Model States
The effect of medication was evaluated in terms of ADHD
symptoms and behavioral change. The model distinguished
four different health states (Table 3). The definition of the
health states was based on the Faber model [29] and en-
hanced with feedback from the expert panel. Where Faber
et al. [29] made a distinction between a suboptimal state for
treatment with IR and the state of non-compliance for
treatment with OROS, the updated model made use of a
consistent health state definition over treatments. The non-
compliance state was replaced by the suboptimal state, now
defined as a state in which medication was skipped and
exposure to medication was insufficient for either IR or
OROS.
In the optimal state, patients were assumed to adhere to
the prescribed medication and consequently not experience
Table 3 Definition of model states
Health state Definition Medication intake per day
OROS IR
Optimal (A)a Optimala daily exposure to medication; remissionb of ADHD symptoms; the child
functions well with this treatment; no significant problems at home, at school, with
peers or during leisure time; the child receives additional care, such as visits to a
specialist, behavioral therapy, extra attention at school, etc
19 39
Suboptimal (B)c Insufficient daily exposure to medication; ADHD symptoms present, but reduced,
different from normal functioning; the child functions considerably well with this
treatment; during short periods, the child experiences problems at home, at school,
with peers or during leisure time; the child receives additional care, such as visits to a
specialist, behavioral therapy, extra attention at school, etc
None 0–29
Treatment stopped (C) Treatment stopped in spite of remaining symptoms of ADHD; noticeable problems at
home, at school, with peers and/or during leisure time; the child experiences more
continuous hinder of those problems; the child receives additional care, such as visits
to a specialist, behavioral therapy, extra attention at school, etc
None None
Remission (D) No medication used; behavioral problems are no more different from normal; no more
additional care needed related to ADHD, such as visits to a specialist, behavioral
therapy, extra attention at school, etc
None None
ADHD attention deficit hyperactivity disorder, IR immediate-release, OROS osmotic-release oral system
a Optimal intake is defined as follows: good compliance with intake of 19/day for OROS and 39/day for IR
b Remission: not different from normal, symptoms of ADHD are at the most sometimes present, but not often or always
c Suboptimal intake: insufficient compliance. Medication is not taken as prescribed, which means no intake for OROS and an average intake of
19/day for IR
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any symptoms of ADHD. Symptoms not directly related to
ADHD but to comorbidity may still be present in this state.
In a suboptimal state, in contrast, patients were assumed
not to adhere properly to their prescribed medication, re-
sulting in symptoms of ADHD and behavior different from
normal behavior for their age group. As a single dose of
OROS was required per day, skipping medication meant no
medication at all in that state. For patients treated with IR,
non-adherence at a mean of 3 prescribed doses per day [9]
was assumed as missing 1, 2 or 3 doses per day, yielding a
mean of 2 missed doses per day in the suboptimal state.
Patients who stopped treatment entirely in spite of re-
maining symptoms of ADHD entered the state ‘treatment
stopped.’ Patients with functional remission not needing
medication for treatment of ADHD entered the state ‘re-
mission.’ In line with the study performed by Faber et al.
[29], we assumed that once in remission, patients remained
in that state, which acted as an absorbing state (Fig. 1). The
consulted psychiatrists indicated that reaching the state of
remission would be exceptional. According to the experts,
the assumption of remission as an absorbing state could
reasonably be made. However, the experts noted that there
may be exceptions where patients experience a relapse
after having reached the state of remission.
Patients in an optimal, suboptimal or treatment stopped
state either remained in that state or transferred to one of
the other states.
2.4 Transition Rates
Variation in effect was modeled based on compliance and
resulting symptom and behavior change (Table 3). Data on
transition rates between model states had to comply with
our specific target population (i.e., children or adolescents
with ADHD who initially had responded suboptimally to
IR because of incorrect intake of medication). Furthermore,
to guarantee the validity of model results, we preferred
transition rates departing from one state to different states
to all originate from the same source (and refer to the same
definition of an optimal and suboptimal state). We con-
sidered transition rates from the Faber model [29]
suboptimal as some of the transition rates were counter-
intuitive and the rates were based on multiple sources (i.e.,
literature and expert opinion). Hence, we performed a
systematic literature review in the PubMed, PsycInfo and
ERIC databases to identify data to determine the transi-
tions. First, we searched for reviews for the period from
January 1, 2008 (the year of publication of the Faber model
[29]) onwards. This search was performed on November 9,
2014. Then, we performed an additional search in the same
databases, directed at recent clinical trials from the publi-
cation date of the most recent identified review onwards.
This second search was performed on December 8, 2014.
Search terms for both searches were as follows: ADHD OR
‘‘attention deficit hyperactivity disorder’’ [title]; AND
methylphenidate OR MPH OR MPH-IR OR MPH-ER OR
pharmaco* [title]; AND effect* OR efficacy OR cost-ef-
fectiveness OR cost-utility [title].
The searches resulted in a total of 121 hits after dupli-
cates were removed. The records were screened by two
researchers independently, in a first round on title and in a
second round on abstract. Where there was conflict, a de-
cision was reached through consensus. The screening and
selection process is summarized in a PRISMA flow dia-
gram in Fig. 2.
The selections based on title and abstract resulted in 16
studies to be included, among which were seven reviews
and nine clinical trials. We were specifically interested in
data from which transition rates for OROS and/or IR could
be derived. Consultation of the reviews yielded several
conclusions. Five reviews presented only mean scores on
specific outcome measures [35, 36] or effect sizes [37–39].
Confidence intervals of effect sizes may be used to calcu-
late transition rates based on a minimal meaningful im-
provement (i.e., defining a certain point on the distribution
at which a patient moves from an optimal towards a sub-
optimal model state). However, as different underlying
studies used different outcomes as the basis for the stated
effect sizes, minimal meaningful improvements (and,
hence, definition of the suboptimal model state) would
differ per outcome measure and per study. Hence, we did
not consider this approach a feasible option within the
scope of this study. Another review presented information
on pharmacokinetics [40]. One other study concerned a
review of cost-effectiveness outcomes, not presenting
specific data on state transitions [41]. None of the reviews
specifically addressed the targeted patient population (i.e.,
children or adolescents who had initially responded sub-
optimally to IR because of incorrect intake of medication).
Hence, we considered the option to base transition esti-
mates on a single study and examined the recent articles for
further informative data. From consultation of these arti-
cles, we noted that seven of the nine articles did not contain
suitable information. Two articles concerned letters to the
optimal
sub optimal
treatment 
stopped
remission
Fig. 1 Graphical representation of the model
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editor [42, 43], one article was written in Iranian language
[44], one article concerned an explanatory study on effect
sizes [45], one article presented mean scores [46] and one
article referred to differences in scores [47]. Another article
presented percentages of patients who improved (a poten-
tially suitable measure for the calculation of transition
probabilities). However, the study considered patients
treated with specific extended-release MPH with 50 %
short-acting and 50 % long-acting components [48]. Two
remaining articles presented data potentially useful for
calculation of transition rates [49, 50]. Garg et al. [49]
found a treatment response of 90.7 % in patients receiving
IR (n = 33) in Northern India. Soutullo et al. [50] stated
that 51 % (95 % CI 31.1–60.6) of European patients
(n = 111) responded to treatment with OROS. The trial
was performed in 48 centers across ten European countries.
However, both articles did not consider the specific patient
population of this study and only one broad rate of
response for the entire treatment period was provided,
whereas our model included more specific transitions be-
tween the optimal and suboptimal states (back and forth)
and accounted separately for patients staying in a specific
state. Furthermore, Garg et al. [49] and Soutullo et al. [50]
used different outcome measures to define response and the
studies were performed in two different treatment popula-
tions. Hence, we considered the information available from
these single clinical trials insufficient to use in the model.
Consequently, we considered the consultation of an expert
panel (from within the Dutch context) superior to using
data from multiple international trials.
Hence, transition rate estimates were attained from
consultation with a Delphi panel of experts (Table 1). We
retrieved all transition rate estimates from one consistent
source (i.e., the expert panel).
The consulted psychiatrists suggested that the group of
patients suboptimally treated with IR would, in particular,
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Fig. 2 PRISMA flow diagram
of systematic literature review.
aReasons: 0 document type:
review (review search)/clinical
trial (clinical trial search); 1
treatment: pharmacological
treatment (of which C1 MPH in
pill form); 2 age group:
6–18 years (child/adolescent); 3
population: ADHD patients (no
combined diagnosis or extreme
symptom type of ADHD); 4
type of outcome measured in
terms of functioning: response,
effect, effectiveness, efficacy,
cost-effectiveness or cost-
utility. ADHD attention deficit
hyperactivity disorder, MPH
methylphenidate. Adapted from
Moher D, Liberati A, Tetzlaff J,
Altman DG, The PRISMA
Group (2009). Preferred
Reporting Items for Systematic
Reviews and Meta-Analyses:
The PRISMA Statement. PLoS
Med 6(6): e1000097. doi:10.
1371/journal.pmed1000097
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experience practical problems with accurate medication
intake schemes during the day or at school. These patients
would need to put more effort into adherence to the ad-
ministration scheme compared with OROS, for which ad-
ministration is limited to once a day. These differences in
effect and effort were reflected in the transition rates be-
tween states.
Transition estimates were attained by blind questionnaires
in two rounds, according to Dutch guidelines for pharma-
coeconomic research [30] and consistent with the Delphi
panel method [51, 52]. The experts were consulted indepen-
dently and were not aware of the identity of the other experts
joining the panel. Before distributing the questions to the
experts, it was decided that consensus was supposed to be
reached after two rounds of answers when (a) feedback of the
experts was clear and (b) when experts did not all change their
answers on the basis of the mean of the feedback of the first
round. The questions for the panel were sent and returned by
email. One of the researchers registered the replies anony-
mously.After all experts had returned the questionnaires, their
answers were combined. The mean value for each question
constituted the basis for the final answer to each question. The
proposals for the final answers as well as the anonymized
individual answers of the participants were reported to the
experts after round 1. In the second round, experts were asked
whether they intended to change their previous answers on the
basis of the proposal for the final answer.
2.5 Utility Values
ADHD is associated with reduced health-related quality of
life [53–56]. The present model was built to assess the cost
utility of OROS versus IR in children and adolescents with
ADHD. Effects were expressed in terms of quality-adjusted
life-years (QALYs). Several members of our research team
were involved in a recent Dutch study that measured the
quality of life of children with ADHD and their parents [57].
The study of van der Kolk et al. [57] was a cross-sectional
study among member of a Dutch ADHD parent association.
Data collection occurred via online questionnaires. The
quality of life of the children (n = 618) was based on parent
proxy ratings, and the quality of life of the caregivers
(n = 590) was based on self-report of the Euroqol (EQ-5D)
questionnaire [57, 58]. The available quality of life data
were highly suitable for inclusion in the current model as
the state definitions of responders and non-responders
closely matched the definition within the current model.
2.5.1 Utility of the Patient
We found a significant difference in quality of life of
patients compliant with prescribed medication compared
with that of non-compliant patients [57]. Compliant pa-
tients reported a quality of life of 0.84 (ages 8–12 years
0.82; ages 13–18 years 0.86) whereas non-compliant
patients reported a quality of life of 0.75 (ages
8–12 years 0.74; ages 13–18 years 0.77) [57]. In the
current model, we included the quality of life values of
the compliant group for the state ‘optimal’ and the uti-
lities of the non-compliant group for the state of ‘sub-
optimal’ functioning. As there was no utility available
for patients who had stopped treatment, we considered it
reasonable to assign to those patients the same utility as
patients in the suboptimal state, as this would constitute
a conservative estimate. Based on the available data,
utility was modeled to differ per model state but not per
treatment type.
2.5.2 Spillover Effects on Caregiver
Family effects [8, 59–62] and negative effects of ADHD on
families in particular [26, 63] have been addressed several
times in the literature. Le et al. [8] suggested that benefits
of ADHD treatment may also extend further than the in-
dividual patient. Brouwer et al. [19] proposed that when
taking a societal perspective, these effects may be added to
the effects experienced by patients. Hence, we considered
it valuable to include spillover effects on the utility of a
parent in the model. In our recent study on quality of life
[57], we found a significant correlation between the quality
of life of the child and the caregiver. No significant dif-
ference was found between the quality of life of parents of
compliant or non-compliant children.
The literature on ADHD is very limited on this aspect,
and our study [57] was the first study to report utilities of
patients with ADHD and caregivers in one study. Further
studies on the specific effect of ADHD on caregiver utility
could not be retrieved from the literature. However, there is
evidence available on the effect of a child with ADHD on
health expenditures of caregivers. Hakkaart et al. [4] stated
that 25 % of the health care expenditures of the caregiver
of a child with ADHD can be attributed to the behavioral
problems of the child. This suggests a considerable influ-
ence of child health on caregiver health. In the absence of
more specific data on the caregiver effects of ADHD, we
searched for publications on caregiver effects in other
diseases. Evidence from the literature on meningitis [23]
suggests that ‘spillover’ health effects on family may
constitute as much as 48 % of the health effects on the
patient. In the case of ADHD, this may be a conservative
estimate as ADHD has been found to be especially
stressful on the direct environment of the patient. Hence,
as an estimate, we included 48 % of caregiver utility in
the model.
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2.6 Cost Parameters
Categories of direct medical and non-medical costs were
kept consistent with the Faber model [29]. These cate-
gories were medication costs, costs of medical consul-
tations, costs of medical and non-medical interventions,
and costs of special education. Costs differed per state,
and in remission, we assumed no costs associated with
ADHD. We assumed all costs except drug costs to be
only dependent on the state and not on the type of
medication (IR or OROS) received by the patient. This
assumption was based on evidence from the literature on
comparable efficacy of IR and OROS under the provision
of full therapy compliance [10–12] and was confirmed by
the expert panel of psychiatrists (Table 1). We consid-
ered different costs for patients when below the age of
12 years and at and above the age of 12 years. This
modeled difference in costs according to current age was
based on consultation of the expert panel (Table 1). The
experts suggested differences in cost when switching
schools (i.e., from primary to secondary education),
which corresponds to the age of 12 years in the Dutch
setting. Health care consumption (i.e., frequencies of
consultations and non-pharmacological interventions)
were extracted from the study performed by Faber et al.
[29]. All costs were valued in euros (€; 2014). Cost
prices were updated based on Hakkaart et al. [64], costs
of special education were updated as reported by the
Dutch Ministry of Education [65] and all costs were
adjusted to 2014 values.
Next to the cost categories consistent with the Faber
model [29], literature and available data of additional cost
categories were searched to determine relevance and fea-
sibility of inclusion in the model. Considered categories
were criminal justice costs, costs of lower-proficiency work
and low income, out-of pocket expenses and spillover ef-
fects on caregivers (i.e., health care costs and production
losses).
2.6.1 Costs of Medication
Individuals in the OROS arm of the model used a full daily
dose of OROS per day in the optimal state and no
medication in all other states. In the IR arm of the study,
participants were assumed to take the full daily dose of IR a
day in the optimal state and on average 1/3 of the daily
dose in the suboptimal state. The daily dose of both OROS
and IR was determined on the basis of the average daily
dose of two age groups (6–12 and 13–18 years) and was
based on IMS health data [66]. Cost of medication was
based on the Dutch price list [67].
2.6.2 Costs of Medical Consultations
Consultation costs concerned contacts with psychiatrists,
other medical specialists, general practitioners, and crisis
contacts. The number of visits per year was dependent on
age and based on the Faber model [29]. Unit prices were
retrieved from the Dutch manual for costing research [64]
and applied to the number of contacts.
2.6.3 Costs of Medical and Non-medical Interventions
Intervention costs included costs of psychosocial and
psychotherapeutic interventions as well as interventions for
educational support (i.e., psycho education, parent training,
behavior child therapy, social skills training, teacher
training, remedial teaching, physical therapy, home train-
ing/care, outpatients’ treatment and institutionalization).
These categories were in line with the Dutch clinical
guidelines for ADHD [9]. Interventions that are provided
on a limited scale in the Netherlands (i.e., neurofeedback,
cognitive training, mindfulness, diet) have not been in-
cluded. The number of contacts was based on the Faber
model [29]. Intervention costs were assumed to occur at
age 6 and at age 12 for 1 year each as experts from the
panel of consulted psychiatrists (Table 1) indicated that
those costs mainly occurred at the moment of switching
between schools. Unit prices were retrieved from the Dutch
manual for costing research [64] and applied to the number
of contacts.
2.6.4 Costs of Special Education
Costs for special education were additional costs per day in
special education. Advice for placement in special educa-
tion was assumed dependent on age. Costs for special
education were considered continuous from age 6 to age 18
in accordance with the experts’ opinion. Probability of
placement was based on the Faber model [29], and unit
prices were based on the Ministry of Education, Culture
and Science [65].
2.6.5 Criminal Justice Costs
Several authors have found a positive relationship between
ADHD in childhood and antisocial behavior and drug use
in (young) adults [68–70]. However, it has to be taken into
account that the high degree of antisocial activity may be
attributed to comorbid conduct disorder [71]. A recent
study by Lichtenstein et al. [72] suggested that criminal
behavior of ADHD patients decreases when medication is
taken consistently. Evidence from the literature suggests
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that data on criminal justice costs related to ADHD are
scarce [20] and especially limited in the European context
[8]. Though these costs are considered highly relevant
especially in the light of a possible relation with medica-
tion intake, the lack of available data resulted in the ex-
clusion of these costs from the current model.
2.6.6 Costs for Educational Support, Cost of Lower-
Proficiency Work and Low Income
Evidence from literature suggests that the impact of ADHD
may exceed the age of school-going children and that it
may result in poor educational performance [4, 8, 63, 73,
74], work achievements [75, 76] and household income
[20, 70, 77, 78]. However, it is not yet clear whether
medical treatment necessarily improves academic perfor-
mance or income, as it may have an effect on some aspects
of academic functioning and not on others [73]. Children
with ADHD often require additional support within the
educational setting [20]. As this study focused on children
between 6 and 18 years, the costs of additional educational
support within the education system up to age 18 were
included within the cost categories ‘costs of medical and
non-medical interventions’ and ‘costs of special education’
in the model (i.e., costs for teacher training, remedial
teaching and costs of special education). When expanding
current projections to a lifetime perspective, long-term
consequences of educational effects (i.e., on work and in-
come) should be included as well.
2.6.7 Out-of-Pocket Expenses
In a Dutch study on out-of-pocket expenses of children and
adolescents with ADHD, Hakkaart et al. [4] presented data
from parents of children with ADHD treated by a pe-
diatrician. The authors found out-of-pocket expenses of
€23.13 (standard deviation €150.35; adjusted to 2014 €) per
annum in the Dutch setting. As the amount of out-of-pocket
expenses is negligible (i.e., not significantly different from
zero) in the study by Hakkaart et al. [4], we did not include
these expenses in the current model.
2.6.8 Spillover on Caregivers (Medical Costs
and Production Losses)
Hakkaart et al. [4] found that mean health care costs of
mothers of children with ADHD were significantly higher
than those of mothers of healthy children. Mean medical
costs per year were €841.93 (adjusted to 2014 €) for
mothers of children with ADHD compared with €178.10 of
mothers of a healthy child. The authors stated that 25 % of
mothers noted that their use of health care services was
related to the behavioral problems of their child [4].
Consequently, we assumed health care costs for a caregiver
of 0.25 9 (€841.93 - 178.10) in the suboptimal and
treatment stopped states and included these costs in the
model. In the optimal state, no additional costs were
assigned.
Hakkaart et al. [4] also collected data on production
losses of mothers of patients with ADHD. The authors
found significantly higher production losses in mothers of
children with ADHD compared with mothers of healthy
controls. Mean annual production losses of mothers (re-
duced efficiency and absence from work) were €2594.03
(adjusted to 2014 €) compared with €779.48 for mothers of
healthy children. As noted above, Hakkaart et al. [4] found
that 25 % of health care costs of the mother were related to
behavioral problems of the child. It seems reasonable to
assume that also 25 % of production losses can be at-
tributed to the behavioral problems of the child. Hence, in
the model, we included mean annual production losses of
0.25 9 (€2594.03 - 779.48) in the suboptimal and treat-
ment stopped states. In the optimal state, no additional
costs were assigned.
2.7 Model Validation
Face validity was ascertained by consulting experts in the
field of ADHD in the Netherlands on clinical aspects of
model structure, model parameters and model input. Fur-
thermore, verification of transition rates was attempted.
Because of the scarce available data, we could only glob-
ally verify the number of patients in an optimal state after
1 year with response percentages from the literature iden-
tified from the systematic review [48–50], which we per-
formed as part of the search for suitable transition rates.
Though the estimates within these studies were based on
different definitions of response or improvement and
studies were performed in different countries, this consti-
tuted the best available data. As our study was performed
in the population of patients who had in the past been
treated with IR and reacted suboptimally because of
problems with medication intake, it was expected that
overall response within the existing literature would be
higher than in our model. This rationale was supported, as
Garg et al. [49] reported a 91 % treatment response in
patients treated with MPH, Sobanski et al. [48] found 78 %
of patients receiving combined short- and long-acting MPH
treatment had reduced symptoms and, according to
Soutullo et al. [50], 51 % of patients responded to treat-
ment with OROS. On the basis of the expert panel esti-
mates within the current model, 22 % of patients treated
with IR and 36 % of patients treated with OROS achieved
a transition from a suboptimal to an optimal state after
1 year. Hence, the transition estimates in our model appear
to be in line with expectations and may even be
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conservative. We further performed scenario analyses to
examine the sensitivity of model results to these
parameters.
2.8 Sensitivity Analyses
Sensitivity analyses were performed for four scenarios: one
scenario assuming equal transition rates for IR and OROS;
a second scenario including an augmented daily dose of
exposure to medication; a third scenario excluding medical
costs and production losses of the caregiver; and a forth
scenario excluding the utility of caregivers. As transition
rates were based on expert opinion (Table 4), we performed
a scenario to estimate the impact of these parameters on the
results. Furthermore, due to issues of noncompliance, the
daily dose data may provide an underestimation of optimal
exposure. To measure the effect of this potential bias, a
scenario was estimated which corrected for noncompli-
ance. Studies by Adler and Nierenberg [16] and Swanson
[79] have estimated noncompliance to amount to 13–64 %
and 20–65 %, respectively. On the basis of these findings,
the scenario considered an average of 40 % noncompliance
in daily dose data used (implying augmentation of the daily
dose by 67 % for both treatment arms). Two additional
scenarios were performed to estimate the effect of the
caregiver costs and effects on the model outcomes. As the
underlying data for the inclusion of these model compo-
nents were limited, the outcomes of the scenario analysis
may provide further incentive for future data collections.
One scenario was performed excluding medical costs and
production losses of caregivers, and another scenario was
performed where utilities of caregivers were excluded.
Monte Carlo results were simulated per scenario, allowing
for uncertainty around all parameter estimates while
analyzing the specific effect of changes of the parameters
of interest. Detailed model parameters are provided in
Table 4.
3 Results
3.1 Transition Estimates
In accordance with the model population, the expert panel
of psychiatrists (Table 1) estimated transition rates for a
patient population initially treated with IR with suboptimal
results because of incorrect intake of medication.
Table 5 displays mean transition percentages per day as
estimated by the expert panel.
Variability in cost parameters was captured by gamma
distributions around the mean, and variability in transition
probabilities entered the model through Dirichlet distribu-
tions [33]. Samples from these prior distributions were
drawn by Monte Carlo simulation. For illustrative purposes
and in the absence of trial data, as a common simplifying
assumption, the standard errors of the cost parameters were
assumed 20 % of the mean. As is common in probabilistic
models, a total of 1000 Monte Carlo simulations were
performed to generate the model results.
Different estimates were attained for patients receiving
OROS and for patients receiving IR. Experts estimated
the probability to transfer from a suboptimal or treatment
stopped state to an optimal state to be higher for patients
receiving OROS than for patients receiving IR. However,
they predicted patients receiving OROS to have a lower
chance of staying in an optimal state than patients re-
ceiving IR. Furthermore, the experts estimated patients
receiving OROS to have a lower chance than patients
receiving IR to stop treatment and a higher chance to go
back to an optimal or suboptimal state when having
stopped the treatment. Transitions from the suboptimal
state to the remaining states appear to differ most between
treatments. All experts considered the transition to a state
of remission to be 0 % per day. This means that the state
‘remission’ becomes redundant. In line with earlier cri-
tical comments on possible relapse after remission, it
becomes clear that remission is seen as an exceptionally
rare state (Fig. 3) such that patients are expected to keep
moving between the optimal, suboptimal and treatment
stopped states instead of reaching a stable state of
remission.
3.2 Model Results and Sensitivity Analyses
Model results indicate dominance of OROS compared with
IR in this population. OROS results in incremental QALY
gains while saving costs. The number of QALYs for OROS
exceeds the number of QALYs for IR by 0.22 (95 %
CI -0.206, 0.228), and the total costs of OROS are esti-
mated to be lower than IR, with incremental cost savings of
€5815 (95 % CI 5661–5969) (Table 6). These results
suggest that, for this patient group, OROS produces better
effects at lower cost compared with IR. The detailed
probabilistic model results of 1000 Monte Carlo simula-
tions are presented on a cost-effectiveness (C/E) plane and
as a cost-effectiveness acceptability curve (CEAC) [80] in
Figs. 4 and 5, respectively. Figure 4 provides details on the
uncertainty around the costs and effect of OROS compared
with IR. The 1000 points in the scatter plot each represent
one simulation result. The x-axis displays the amount of
incremental QALY gains or losses and the y-axis shows the
incremental costs expressed in euros.
The results of the C/E plane show that the majority of
data points appear in the southeast quadrant, with lower
costs and higher effects of OROS compared with IR, which
indicates dominance of OROS versus IR.
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Table 4 Detailed model parameters and assumptions (in 2014 €)
Parameter Description Source
General parameters
Discount rate Costs discounted at constant
discount rate of 4 %, effects at constant
discount rate of 1.5 %
College voor Zorgverzekeringen [30]
Patient age All patients assumed to enter
the model at age 6
Indicatie Concerta, Landelijke Stuurgroep
Multidisciplinaire Richtlijnontwikkeling
in de GGZ [9]
Monte Carlo random sampling N = 1000 Briggs et al. [33]
Transition probabilities
IR: A to A Dirichlet, mean 8.97 Expert panel data
IR: A to B Dirichlet, mean 90.20 Expert panel data
IR: A to C Dirichlet, mean 1.01 Expert panel data
IR: A to D 0 Expert panel data
IR: B to A Dirichlet, mean 22.47 Expert panel data
IR: B to B Dirichlet, mean 54.25 Expert panel data
IR: B to C Dirichlet, mean 23.28 Expert panel data
IR: B to D 0 Expert panel data
IR: C to A Dirichlet, mean 16.58 Expert panel data
IR: C to B Dirichlet, mean 10.26 Expert panel data
IR: C to C Dirichlet, mean 73.16 Expert panel data
IR: C to D 0 Expert panel data
OROS: A to A Dirichlet, mean 6.25 Expert panel data
OROS: A to B Dirichlet, mean 93.75 Expert panel data
OROS: A to C 0 Expert panel data
OROS: A to D 0 Expert panel data
OROS: B to A Dirichlet, mean 58.91 Expert panel data
OROS: B to B Dirichlet, mean 23.81 Expert panel data
OROS: B to C Dirichlet, mean 17.27 Expert panel data
OROS: B to D 0 Expert panel data
OROS: C to A Dirichlet, mean 24.21 Expert panel data
OROS: C to B Dirichlet, mean 14.21 Expert panel data
OROS: C to C Dirichlet, mean 61.58 Expert panel data
OROS: C to D 0 Expert panel data
Utility: patient (8–12 years)
Optimal Beta, mean 0.82, se 0.0979 van der Kolk et al. [57]
Suboptimal Beta, mean 0.74, se 0.01588 van der Kolk et al. [57]
Treatment stopped Beta, mean 0.74, se 0.01588 van der Kolk et al. [57]
Utility: patient (13–18 years)
Optimal Beta, mean 0.86, se 0.01097 van der Kolk et al. [57]
Suboptimal Beta, mean 0.77, se 0.02645 van der Kolk et al. [57]
Treatment stopped Beta, mean 0.77, se 0.02645 van der Kolk et al. [57]
Utility: caregiver
Optimal Beta, mean 0.85, se 0.00897 van der Kolk et al. [57]
Suboptimal Beta, mean 0.83, se 0.01499 van der Kolk et al. [57]
Treatment stopped Beta, mean 0.83, se 0.01499 van der Kolk et al. [57]
Drug costs
Daily dose OROS: child 6–12 years (mg) 31.70 IMS Health BV [66]
Daily dose OROS: child 13–18 years (mg) 39.10 IMS Health BV [66]
Daily dose IR: child 6–12 years (mg) 22.00 IMS Health BV [66]
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Table 4 continued
Parameter Description Source
Daily dose IR: child 13–18 years (mg) 29.20 IMS Health BV [66]
Costs/mg OROS 0.05 Zorginstituut Nederland [67]
Costs/mg IR 0.01 Zorginstituut Nederland [67]
Pharmacy fee/3 months 7.0 Zorginstituut Nederland [67]
Consultation costs Incurred by children between 6 and
18 years of age
Number of visits per year: child B12 State A State B State C
Psychiatrist 2.28 3.42 5.00 Faber et al. [29]
Other specialist 0 0 1.38 Faber et al. [29]
General practitioner 0 0 0.58 Faber et al. [29]
Crisis contacts 0.57 1.49 2.71 Faber et al. [29]
Number of visits per year: child[12 State A State B State C
Psychiatrist 2.43 3.57 5.00 Faber et al. [29]
Other specialist 0 0 0.11 Faber et al. [29]
General practitioner 0 0.29 0.43 Faber et al. [29]
Crisis contacts 0.35 1.28 3.00 Faber et al. [29]
Costs per visit
Psychiatrist 113.53 Hakkaart et al. [64]
Other specialist 75.15 Weighted average psychiatrist and
medical specialist: 46:34 [29, 64]
General practitioner 31.22 Hakkaart et al. [64]
Crisis contacts 256.20 Based on Tariffs AWBZ-institutions
2005 [88]
Intervention costs Incurred by children aged 6 and 12 years
Transferred % of patients: child B12 State A State B State C
Psycho education 0.89 0.93 1.00 Faber et al. [29]
Parent training 0.49 0.76 0.79 Faber et al. [29]
Behavior therapy child 0.07 0.23 0.57 Faber et al. [29]
Social skills training (SOVA) 0.19 0.28 0.38 Faber et al. [29]
Teacher training 0.43 0.57 0.66 Faber et al. [29]
Remedial teaching 0.37 0.51 0.77 Faber et al. [29]
Physical therapy 0 0 0 Faber et al. [29]
Home training/care 0.04 0.13 0.33 Faber et al. [29]
Outpatients’ treatment 0 0 0.25 Faber et al. [29]
Institutionalization 0 0 0.03 Faber et al. [29]
Transferred % of patients: child[12 State A State B State C
Psycho education 0.94 0.90 0.89 Faber et al. [29]
Parent training 0.31 0.44 0.74 Faber et al. [29]
Behavior therapy child 0.09 0.28 0.56 Faber et al. [29]
Social skills training (SOVA) 0.07 0.26 0.53 Faber et al. [29]
Teacher training 0.10 0.33 0.32 Faber et al. [29]
Remedial teaching 0.02 0.39 0.47 Faber et al. [29]
Physical therapy 0 0 0 Faber et al. [29]
Home training/care 0 0.1 0.13 Faber et al. [29]
Outpatients’ treatment 0 0 0.26 Faber et al. [29]
Institutionalization 0 0 0.04 Faber et al. [29]
Number of visits per year: child B12 State A State B State C
Psycho education 2.64 3.64 3.86 Faber et al. [29]
Parent training 8.34 7.92 14.01 Faber et al. [29]
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Figure 5 shows a graphical presentation of the CEAC,
displaying the probability that OROS is cost effective
compared with IR given different values of maximum
threshold for society. The threshold values in terms of
euros are shown on the x-axis and the probability of OROS
being cost effective is displayed on the y-axis.
The CEAC displays data points within all four quad-
rants, with the majority of data points in the southeast
Table 4 continued
Parameter Description Source
Behavior therapy child 13.18 11.80 13.15 Faber et al. [29]
Social skills training (SOVA) 9.15 9.79 9.15 Faber et al. [29]
Teacher training 1.75 3.73 3.94 Faber et al. [29]
Remedial teaching 20.00 20.00 20.00 Faber et al. [29]
Physical therapy 6.00 0 0 Faber et al. [29]
Home training/care 10.00 11.15 14.31 Faber et al. [29]
Outpatients’ treatment 0 0 51.75 Faber et al. [29]
Institutionalization 0 0 90.00 Faber et al. [29]
Number of visits per year: child[12 State A State B State C
Psycho education 2.78 3.57 5.42 Faber et al. [29]
Parent training 5.91 8.24 13.74 Faber et al. [29]
Behavior therapy child 10.00 11.44 12.88 Faber et al. [29]
Social skills training (SOVA) 9.15 11.44 10.59 Faber et al. [29]
Teacher training 2.00 2.50 3.73 Faber et al. [29]
Remedial teaching 20.00 20.00 20.00 Faber et al. [29]
Physical therapy 0 0 0 Faber et al. [29]
Home training/care 0 10.00 10.06 Faber et al. [29]
Outpatients’ treatment 0 0 51.75 Faber et al. [29]
Institutionalization 0 0 135.00 Faber et al. [29]
Costs per visit
Psycho education 111.17 Based on Tariffs AWBZ-institutions
2005 [88]
Parent training 104.15 Based on Tariffs AWBZ-institutions
2005 [88]
Behavior therapy child 111.17 Based on Tariffs AWBZ-institutions
2005 [88]
Social skills training (SOVA) 111.17 Based on Tariffs AWBZ-institutions
2005 [88]
Teacher training 76.05 Based on Tariffs AWBZ-institutions
2005 [88]
Remedial teaching 58.49 Based on Dutch Society of Remedial
Teachers [89]
Physical therapy 39.84 Hakkaart et al. [64]
Home training/care 114.52 Based on Health care insurance board [90]
Outpatients’ treatment 150.57 Hakkaart et al. [64]
Institutionalization 301.09 Hakkaart et al. [64]
Special education costs Incurred by children between 6 and
18 years of age
State A State B State C
Advice placement special education (%): child B12 0.015 0.1224 0.4356 Faber et al. [29]
Advice placement special education (%): child[12 0.0007 0.0863 0.3711 Faber et al. [29]
Additional costs special education/day 13.63 Based on Ministry of Education,
Culture and Science [65]
IR immediate-release, OROS osmotic-release oral system, SE standard error
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quadrant [81]. The probability of OROS being cost effec-
tive ranges between 93 and 99 %. The CEAC does not
cross the y-axis at 0 as some data points in the C/E plane
display cost savings of OROS compared with IR. Fur-
thermore, the CEAC does not asymptote to 1 because a part
of the observed data points on the C/E plane show negative
incremental effects.
Sensitivity analyses indicate that when transition rates of
OROS are equal to the transitions of IR (scenario 1), the
incremental QALYs gained for OROS compared with IR
amount to 0.00 and costs of treatment with OROS appear
slightly higher than treatment with IR, with additional in-
cremental costs of €800 (Table 6). These results in terms of
incremental costs are close to the results of the Faber model
[29], and the incremental effects are reduced to zero.
Model results, thus, are strongly dependent on accurate
estimates of transition probabilities as these determine how
fast patients move between model states and, hence, how
often they stay in more or less ‘expensive’ states.
The scenario with an augmented daily dose of exposure
to medication (scenario 2) resulted in slightly lower sav-
ings compared with the base scenario (savings of €4502
and QALY gains of 0.21).
Exclusion of medical costs and production losses of
caregivers from the model results in incremental cost
savings of €4930 and incremental QALY gains of 0.22.
When utility of caregivers is excluded, there are in-
significant changes in incremental costs (€5900) and a
decrease in incremental QALY gains to 0.15. This incre-
mental QALY decrease is explained by the fact that 48 %
of the QALYs of the patient have been added to account for
effect on a caregiver.
4 Discussion and Conclusions
Policymakers increasingly use cost-effectiveness analyses
to inform decision making on competing health care in-
terventions. Health economic models facilitate these ana-
lyses by providing a framework to combine information
from different sources and enable probabilistic estimations.
Within health care there has been debate on which per-
spective to take in such models. In the Netherlands, a so-
cietal perspective is common according to the health
economic guidelines. Lately, there have been voices to
even include broader effects (i.e., exceeding the patient and
Table 5 Mean (standard deviation) transitions per day (in %) as estimated by expert panel
From/to Optimal Suboptimal Treatment stopped Remission
IR
Optimal 8.79 (6.34) 90.20 (7.84) 1.01 (2.02) 0 (0)
Suboptimal 22.47 (21.41) 54.25 (14.21) 23.28 (11.74) 0 (0)
Treatment stopped 16.58 (8.02) 10.26 (8.60) 73.16 (15.94) 0 (0)
OROS
Optimal 6.25 (9.46) 93.75 (9.46) 0 (0) 0 (0)
Suboptimal 58.91 (21.03) 23.81 (12.51) 17.27 (9.82) 0 (0)
Treatment stopped 24.21 (11.73) 14.21 (15.81) 61.58 (23.98) 0 (0)
IR immediate-release, OROS osmotic-release oral system
“I usually aim at stopping medication after approximately 2 years of treatment and starting 
from that moment once a patient has been well controlled for approximately 3 years, one can 
speak of remission.”
“Even in a state of remission, children who suffer from ADHD will still experience long-term 
effects of ADHD such as impact on emotional development.” “In general there are few 
children who actually achieve remission as I work with children between 0 and 18 years of 
age…One could question whether it is actually possible to achieve complete remission of 
ADHD for a child.”
“Remission is a state in which a patient has no complaints over a certain time horizon. Often 
this time horizon is considered to be half a year.”
“The aim of treatment is not to let symptoms disappear completely but to keep them under 
control. Total disappearance of symptoms is actually not possible…that would mean that a 
child is cured and that is very rare and is achievable over a timeframe of several years.”
Fig. 3 Expert comments on
state of remission. ADHD
attention deficit hyperactivity
disorder
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exceeding health care) [19]. This may be especially rele-
vant to illness in children and disorders, which have a high
impact on third parties (such as in the setting of ADHD).
The presented model adds to the current movement to-
wards broader considerations in cost-effectiveness ana-
lyses. We have presented a model compliant with the
current health economic guidelines and at the same time
considered, and where possible included, broader societal
aspects to increase the comprehensiveness of the model
results. Hence, the results of this study can be used as direct
input to policymakers’ decision making.
Model results indicate that, for children responding
suboptimally to treatment with IR, the beneficial effect of
OROS on compliance may be worth the additional
medication costs. The current model was based on the
Faber model [29], but model structure and input were
improved and the model was enhanced with additional
broader societal parameters. Transition rates consistent
Table 6 Mean model results and sensitivity analyses of Monte Carlo simulations (n=1000)
Description Incremental costs (2014 €) Incremental QALYs
Base case -5815 0.22
Scenario 1 Transition rates of OROS equal to transition rates of IR 800 0.00
Scenario 2 Daily dose of medication ?66 % -4502 0.21
Scenario 3 Medical costs and production losses of caregiver excluded -4930 0.22
Scenario 4 Utility of caregivers excluded -5900 0.15
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with our model structure could not be obtained from one
source of literature. Therefore, we chose to consult an
expert panel to provide transition rate estimates for all
model states. Guidelines for health economic analysis state
that in the case where data are not available, the use of
input from an expert panel is accepted, provided that a
scientific method is used. The experts were consulted using
a Delphi method as described in the Dutch guidelines for
pharmacoeconomic analyses [30]. In the case of transition
probabilities, the use of an expert panel was crucial and far
from ideal. However, it was necessary since data were not
available from literature. We attempted to validate the
expert transitions; however, because of the scarce lit-
erature, this was only partly possible. Hence, a scenario
analysis was performed to examine sensitivity of model
results to these parameters. This analysis showed that
model results are very sensitive to estimated transitions.
Hence, empirical data to improve these estimates are
strongly needed. As elaborated in the ‘‘Methods’’ section,
we adhered to the formal requirements of the Delphi
method and present our results with caution as the focus of
this study was to build an up-to-date model for evaluation
of OROS compared with IR rather than to gather com-
prehensive input to the model. One should note that par-
ticipating experts received a small compensation, which
was strictly limited to compensation for their invested time.
The authors consider the collection of empirical data the
necessary next step for further research.
In the current model, important societal costs and effects
have been included (i.e., health care costs of caregiver,
production losses of the caregiver and utilities of the care-
giver). However, several aspects could not be covered,
because of limited availability of data. Estimates of justice
costs (i.e., incarceration costs, victim costs, etc.) could not
be included, because of a lack of data in the considered age
group and in the European context. Out-of-pocket expenses
were not included as there was evidence from the Dutch
literature that these costs were negligible [4]. However,
when applying the current model to a different setting,
country adaptation may be necessary, as a Belgian study
[63] suggests differences in amounts of out-of-pocket ex-
penses. These differences may be attributed to differences
in sampling methods between the studies, but differences in
health care systems may also play a role and necessitate
model adaptation. Long-term effects on work and income
have not been included in the model but are considered
relevant. When taking a long-term perspective, these costs
should be included in the model. Furthermore, in the current
model, health care costs and production losses of the care-
giver, which should be attributed to the behavioral problems
of the child, were estimated at 25 % of the total production
losses. Mothers of children with ADHD had indicated that
this percentage of their health care expenditures was related
to the behavioral problems of their child. As it might be
ethically difficult for a mother to blame her child for her
medical problems, this estimate may be conservative. On
the other hand, heritability of ADHD may point towards
high medical expenditures of mothers for their own medical
needs. Hence, in total, the chosen percentage might be a
good estimate. Concerning the utilities of caregivers, the
literature was especially limited. Hence, additional data are
necessary to provide a better basis for future analyses. So,
especially, concerning societal costs, available data were
extremely scarce, and we emphasize the necessity for ad-
ditional studies to close this gap.
Earlier cost-effectiveness results of the Faber model [29]
resulted in incremental costs of €276 and incremental
QALY gains of 0.13 of OROS compared with IR. The
calculations in the current study resulted in mean incre-
mental cost savings of €5018 and mean incremental QALY
gains of 0.22. The differences in costs can be explained by
substantial revision of transition rates based on expert
panel estimates, differences in model structure (e.g., con-
sistent model states over treatment alternatives and omis-
sion of the state of ‘remission’ because of experts’
opinion), update of cost parameters to 2014 values (in-
cluding a slight price deflation on drug costs of OROS) and
difference in time horizon. Compared with the transition
rates presented by Faber et al. [29], which were based on a
collection of different sources, the experts’ transition rates
based on the expert panel presented in this study showed
significant differences. In the Faber model [29], no dif-
ferentiation was made between the probability of patients
in an optimal or in a suboptimal state to stop treatment (IR
treatment arm). The same was true for the probability of
patients in the optimal or suboptimal state to achieve
functional remission or to transfer to a non-compli-
ant/suboptimal state (OROS treatment arm). With respect
to these probabilities, the Faber model [29] treated patients
in an optimal and suboptimal state as being equal. These
assumptions appear rather strong as they a priori prevented
differences in compliance affecting the chance of func-
tional remission or termination of treatment. In this study,
on the contrary, the experts indicated clear differences
between these transition probabilities (Table 5). Faber
et al. [29] furthermore assumed a chance of moving from
an optimal to a suboptimal state in the IR treatment arm to
be 0 and the chance to stop treatment when non-compliant
as 0 in the OROS arm. Both these assumptions appear
counter-intuitive as they imply that a patient treated with
IR may not miss a dose once he has achieved an optimal
state and a non-compliant patient receiving OROS may not
stop treatment at all. In the current study, the expert panel
estimated all transition rates without assumptions before-
hand to achieve a consistent framework of transition
probabilities. As the transitions have a direct effect on how
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long patients remain in a state, these estimates have a
strong influence on both incremental costs and effects and
mainly explain the difference between the current model
outcomes and those of the Faber model [29]. The transition
estimates by the expert panel showed that patients receiv-
ing OROS were expected to be less likely to stop treatment,
which corresponds to the findings from the literature on
treatment duration and continuity [14, 15]. Furthermore,
more patients receiving OROS were expected to move
from a suboptimal state or a state were treatment was
stopped back to an optimal state compared with patients
receiving IR. These results are in line with the literature, as
this suggests improved compliance of patients receiving
OROS compared with those receiving IR [16–18]. How-
ever, the expert panel predicted the patients treated with
OROS to have a lower probability to remain in an optimal
state than patients receiving IR. This constitutes an unex-
pected finding given the literature on better compliance of
patients receiving OROS [16–18]; hence, we consider
collection of additional empirical data necessary.
The treatment effects in terms of quality of life were
based on parental preferences. These were taken from an
existing study by van der Kolk et al. [57]. It has been
shown that the value of quality of life valuation by children
themselves may be questionable, particularly because of
lack of language, cognitive limitations, long-term per-
spective [82, 83] and conceptual difficulty of the standard
gamble task [84]. Therefore, parental preferences were
considered most appropriate for the young population of
the current study. However, we are aware of the short-
comings of this approach, namely the inability of parents to
accurately estimate invisible and subjective aspects of their
child’s quality of life, such as social and emotional func-
tioning [82–85]. This limitation may lead to inaccurate
estimates and a possible overestimation of the child’s dis-
ability [86]. Besides the utility of the patient, we also in-
cluded caregiver utility in the model. The proportion
included was based on very limited evidence from the lit-
erature. As a scenario analysis showed, model results are
sensitive to these utilities. Hence, additional data are
needed. As economic cost-utility analysis and expressing
outcomes in terms of QALYs is not yet common in the
field of child and adolescent mental health [87], it may
remain relevant for further studies to investigate results
based both on costs/QALY and on costs per different (more
clinically focused) outcome measures.
Severity of ADHD was not specified, but average
severity was assumed in the model. One could, for in-
stance, specify severity of ADHD in the model by distin-
guishing between the following categories of severity: (1)
severe: no remission achievable; (2) moderate: 50 % re-
mission achievable; and (3) mild: 100 % remission
achievable. Furthermore, taking account of comorbidities
may affect the costs entered in the model in such a way that
part of the costs, e.g., special education, may not be at-
tributed to ADHD alone but to behaviors which arise from
a combination of comorbidities. In addition, long-term
learning delay and emotional development problems were
not taken into account in the current model. Hence, it
should be noted that the current methodology is yet in-
complete and that consideration of additions for long-term
effects or consideration of different types of outcome
measures to better account for the specific effects of mental
health interventions may be necessary to improve the ex-
isting methodology.
Finally, as the focus of the study was the construction
and demonstration of a broad and up-to-date probabilistic
model compliant with current health economic method-
ology in this population rather than the provision of ex-
tensive input to the model, the model results should be
interpreted with care. As can be seen from our results, future
research should especially be directed at the collection of
empirical data on transition estimates. We specifically
suggest the collection of data from observational studies
with large numbers of ADHD patients receiving (different
types of) pharmaceutical treatment(s) compared with a
control group of ADHD patients not treated with medica-
tion. It would be especially valuable to obtain data on
treatment response (i.e., transition rates), health care use,
school absence and performance, criminal activities and
quality of life for these groups. To better cover the broad
societal aspects, a very valuable and relevant addition
would be data on the medical consumption, absence from
work and utility of the caregivers and siblings as well. This
information would be a valuable and necessary addition to
the current model as it would lead to an increase in accuracy
of the results and form a valuable basis for clinical and
policy recommendations.
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